Gastric Cancer News and Research

RSS

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018

World Stomach Day: International initiative to raise awareness and support for a vital organ

Tuesday, 2 October 2018 marks the first ever World Stomach Day, an international initiative to raise awareness and support for one of our most vital organs.

3 Oct 2018

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

As one of the most common malignant tumors, gastric cancer occupies the second leading cause of cancer-related deaths worldwide with an increasing trend.

18 Sep 2018

Study identifies potential guidance to treat gastric cancer patients

Researchers from Wake Forest Baptist Medical Center and Tianjin Medical University Cancer Institute and Hospital have discovered that gastric cancer tissue samples bearing mutation of a specific gene, MUC16, too are associated with higher tumor mutation loads.

14 Aug 2018

Scientists find new molecular biomarker for gastric cancer

Although immunotherapy is seen as a very promising treatment for cancer, currently only 20 to 30 percent of patients respond positively. Being able to identify the people most likely to benefit from the costly therapy is a Holy Grail for oncologists.

9 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

UC Riverside researcher receives grants to advance cancer, ALS research

Maurizio Pellecchia, who holds the Daniel Hays Chair in Cancer Research at the University of California, Riverside, has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

21 Jun 2018

Between death and deportation

This is the beginning of a plea written by a 13-year-old girl to the Department of Homeland Security. The goal: to get her mother the insurance coverage she would need to enter a clinical trial.

18 May 2018

Scientists develop integrated system for early diagnosis of diseases using wearable monitors

Researchers from the Wolfson Faculty of Chemical Engineering at the Technion-Israel Institute of Technology have developed an integrated system for early diagnosis of diseases using wearable monitors.

16 May 2018

Preclinical study suggests ARID1a mutations may help predict immunotherapy success

Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University of Texas MD Anderson Cancer Center.

8 May 2018

NF-κB1 gene known to drive cancer development is critical for preventing stomach cancers

Melbourne researchers have made the surprise discovery that the 'odd one out' in a family of proteins known to drive cancer development is instead critical for preventing stomach cancers.

24 Apr 2018

Biomarkers may help predict prognosis of gastric cancer patients with alcohol consumption habits

Alcohol consumption has been identified as a modifiable risk factor for cancers such as gastric cancer. A new report in the The American Journal of Pathology sheds light on how specific proteins interact with alcohol, and how that interplay impacts survival and response to platinum-based adjuvant chemotherapy in patients with gastric cancer who may or may not still be drinking.

10 Jan 2018

Researchers use genomic technologies to better understand risk factor for stomach cancer

A research team led by National University Health System and Duke-NUS Medical School has used genomic technologies to better understand intestinal metaplasia, a known risk factor for gastric (stomach) cancer.

5 Jan 2018

Scientists identify new strategies used by Helicobacter pylori to target mitochondria

Helicobacter pylori is a bacterial pathogen that colonizes the stomach of approximately half of the world's population. Infection with H. pylori is acquired in childhood and lasts for decades.

29 Nov 2017

Elevated oral pathogens, less bacterial diversity linked to risk of developing precancerous gastric lesions

Elevated pathogen colonization and a lack of bacterial diversity in the mouth were identified in people with precancerous lesions that could precede stomach cancer, finds a new study led by New York University College of Dentistry and New York University School of Medicine.

28 Nov 2017

Flies could act as autonomous bionic drones to help monitor disease outbreaks

An international research team led by Nanyang Technological University, Singapore have proposed that swarms of flies can be used to help monitor disease outbreaks.

25 Nov 2017

Researchers identify mechanisms through which H. pylori bacteria cause gastric cancer

Gastric cancer is one of the five most fatal types of cancer. According to the statistics of the World Health Organization, about 750,000 patients die each year after developing the disease. The main cause is thought to be the bacterium Helicobacter pylori (H. pylori).

7 Nov 2017